A Randomized, Single-Blind, Parallel-Group Study To Evaluate The Effects Of Ts-134 On Ketamine- Induced Bold Signals In Resting Fmri In Healthy Adult Subjects

Therapies targeting glutamatergic system for schizophrenia have yielded mixed results across studies to date, and there is a critical absence of validated target-engagement biomarkers. We evaluated the dose-dependent target engagement of TS-134, a metabotropic glutamate receptor 2/3 (mGlu2/3) agonist using ketamine-evoked pharmacoBOLD in healthy volunteers.